These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25230720)

  • 1. Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy.
    Italiano D; Bianchini E; Ilardi M; Cilia R; Pezzoli G; Zanettini R; Vacca L; Stocchi F; Bramanti P; Ciurleo R; Di Lorenzo G; Polimeni G; de Luise C; Ross D; Rijnbeek P; Sturkenboom M; Trifirò G
    J Neural Transm (Vienna); 2015 Jun; 122(6):799-808. PubMed ID: 25230720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.
    Ooba N; Yamaguchi T; Kubota K
    Drug Saf; 2011 Apr; 34(4):329-38. PubMed ID: 21417505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease.
    Nakaoka S; Ishizaki T; Urushihara H; Satoh T; Ikeda S; Morikawa K; Nakayama T
    Intern Med; 2011; 50(7):687-94. PubMed ID: 21467699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
    Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.
    Tan T; Cabrita IZ; Hensman D; Grogono J; Dhillo WS; Baynes KC; Eliahoo J; Meeran K; Robinson S; Nihoyannopoulos P; Martin NM
    Clin Endocrinol (Oxf); 2010 Sep; 73(3):369-74. PubMed ID: 20550538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease.
    Levin J; Neudert J; Zwermann L; Näbauer M; Bötzel K
    J Neurol; 2011 Nov; 258(11):2097-9. PubMed ID: 21562724
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopamine agonists and the risk of cardiac-valve regurgitation.
    Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
    N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
    Auriemma RS; Pivonello R; Perone Y; Grasso LF; Ferreri L; Simeoli C; Iacuaniello D; Gasperi M; Colao A
    Eur J Endocrinol; 2013 Sep; 169(3):359-66. PubMed ID: 23824978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
    Pullan PT
    Intern Med J; 2009 Apr; 39(4):213-5. PubMed ID: 19402858
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment with cabergoline in Parkinson disease can cause heart damage. Continuous treatment requires clinical and echocardiographic check ups].
    Lökk J
    Lakartidningen; 2007 Oct 3-9; 104(40):2892-4. PubMed ID: 17966806
    [No Abstract]   [Full Text] [Related]  

  • 13. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study.
    Peralta C; Wolf E; Alber H; Seppi K; Müller S; Bösch S; Wenning GK; Pachinger O; Poewe W
    Mov Disord; 2006 Aug; 21(8):1109-13. PubMed ID: 16622856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk assessment and follow-up of valvular regurgitation in Parkinson patients treated with cabergoline.
    Fietzek UM; Riedl L; Ceballos-Baumann AO
    Parkinsonism Relat Disord; 2012 Jun; 18(5):654-6. PubMed ID: 21908226
    [No Abstract]   [Full Text] [Related]  

  • 16. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
    Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
    Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010.
    Nakaoka S; Ishizaki T; Urushihara H; Satoh T; Ikeda S; Yamamoto M; Nakayama T
    PLoS One; 2014; 9(6):e99021. PubMed ID: 24906013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
    Simonis G; Fuhrmann JT; Strasser RH
    Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cabergoline in hyperprolactinemia and valvular heart disease].
    Vargas ML; Cervantes CE; Hernando CA; Da Costa CV
    Endocrinol Nutr; 2009 Oct; 56(8):412-7. PubMed ID: 19959151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
    Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
    Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.